 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- CART-19 / Shanghai Unicar
Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL (Room 6A (San Diego Convention Center)) - Nov 3, 2023 - Abstract #ASH2023ASH_5051;
P1/2
Our clinical studies demonstrated the safety and high efficacy of ssCART-19 with IL-6 gene silencing in patients with relapsed/refractory B-ALL. These findings support the potential of ssCART-19 as a promising therapeutic approach for this challenging patient population.
- | CART-19 / Shanghai Unicar
Trial completion date, Trial primary completion date: CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - May 19, 2022
P1/2, N=15, Recruiting, Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
These findings support the potential of ssCART-19 as a promising therapeutic approach for this challenging patient population. Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2020 --> Jan 2023
- || CART-19 / Shanghai Unicar
New P1/2 trial: CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Apr 1, 2019
P1/2, N=15, Recruiting, Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd